Big Pharmas Back $300m Neglected Disease Fund
Cash For Projects 'Wall Street and Silicon Valley Pay Little Attention To'
Executive Summary
Adjuvant Capital believes its fund will ultimately lead to greater access to medical advances in low-income countries while making a healthy return for its high-profile investors.
You may also be interested in...
Novartis, Takeda See Industry Better Prepared For Next Pandemic
Novartis and Takeda’s R&D efforts saw an impact from the COVID-19 pandemic, but both Lutz Hegemann and Andrew Plump believe that when the next pandemic hits, the industry and regulators will be better prepared for it.
Novartis and Gates Foundation Ink Sickle Cell Gene Therapy Pact
The Swiss major envisions developing an accessible in vivo gene therapy for SCD that could potentially be administered once directly to the patient without the need to modify cells in a lab.
Abingworth Offers Home For Big Pharma Pipeline Projects
The UK-headquartered life sciences investment firm has comfortably exceeded its target of $350m for a fund dedicated to taking on late-stage products, incurring all the clinical and regulatory risk and receiving a pre-negotiated return once the drug is approved.